Skip to main content

BioGx Gets CE Marking for Six Meningitis, Antibiotic Resistance Tests

NEW YORK (GenomeWeb) – BioGx announced today that it has received CE marking for six tests for various meningitis infections and antibiotic-resistant organisms.

The tests are designed to run on Becton Dickinson's PCR-based BD Max platform. The meningitis tests cover viral meningitis based on DNA from HSV-1, HSV-2, and VZV; bacterial meningitis based on DNA from Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae; and bacterial meningitis ELGBS based on DNA from Escherichia coliListeria spp., and Group B Streptococcus.

The antibiotic resistance tests include ones for carbapenem resistance in organisms with the resistance genes KPC, NDM-1, and OXA-48; carbapenem and colistin resistance in organisms with the resistance genes VIM, GES, and mcr-1; and vancomycin resistance in organisms with the resistance genes vanA, vanB, vanC1, and vanC2/3.

Birmingham, Alabama-based BioGx now has 11 CE-marked tests that run on the BD Max system — including ones for influenza A, influenza B, respiratory syncytial virus, mycoplasma/ureaplasma genital infections, Pneumocystis jirovecii infection, tuberculosis, and Bordetella infection — and expects to receive CE marking on an additional 10 before the end of the year.